Bullish
GSK and Spero Therapeutics announced that the FDA has approved Utebzi (tebipenem pivoxil), the first and only oral carbapenem antibiotic for adults wi...
Bullish
GSK announced its intention to acquire U.S. biopharmaceutical firm Nuvalent for approximately $10.6 billion, offering $124 per share, a 40% premium. T...
Bullish
GSK and Ionis Pharmaceuticals' genetic medicine, bepirovirsen, showed functional curative potential in chronic hepatitis B (CHB) in two Phase III stud...